Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial.

Halawi H, Khemani D, Eckert D, O'Neill J, Kadouh H, Grothe K, Clark MM, Burton DD, Vella A, Acosta A, Zinsmeister AR, Camilleri M

The lancet. Gastroenterology & hepatology27 Sept 2017Cited by 180 (Europe PMC)

PMID28958851DOI10.1016/s2468-1253(17)30285-6PepBankPUB-28958851

Publisher page PubMedAsk about this study

Jump to 11 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialMechanism
In obese adults, liraglutide delayed gastric emptying of solids at 5 weeks more than placebo.
In plain wordsIn obese adults, liraglutide slowed how fast the stomach emptied solid food at 5 weeks, compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseGastric emptying of solids (T1/2 delay) at 5 weeks
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
3·0 mg · subcutaneous · 5 weeksAs given in this study (human).
Measurements
Gastric emptying delay median
70 min
liraglutide, 5 weeks
Gastric emptying delay median
4 min
placebo, 5 weeks
Source sentences
Summary
Compared with placebo, liraglutide delayed gastric emptying of solids at 5 weeks (median 70 min [IQR 32 to 151] vs 4 min [-21 to 18]; p<0·0001)
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885101
02HumanRandomized controlled trialMechanism
In obese adults, liraglutide delayed gastric emptying of solids at 16 weeks more than placebo.
In plain wordsIn obese adults, liraglutide slowed how fast the stomach emptied solid food at 16 weeks, compared with placebo.
Peptide
Liraglutide
Outcome
IncreaseGastric emptying of solids (T1/2 delay) at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Primary
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Compared with placebo, liraglutide delayed gastric emptying of solids at 5 weeks (median 70 min [IQR 32 to 151] vs 4 min [-21 to 18]; p<0·0001) and 16 weeks (30·5 min [-11 to 54] vs -1 min [-19 to 7]; p=0·025).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885102
03HumanRandomized controlled trialEfficacy outcome
In obese adults, weight loss at 5 weeks was significantly greater with liraglutide than with placebo.
In plain wordsIn obese adults, liraglutide led to more weight loss at 5 weeks than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 5 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3·0 mg · subcutaneous · 5 weeksAs given in this study (human).
Source sentences
Summary
There was also significantly greater weight loss in the liraglutide group than in the placebo group (at 5 weeks: median 3·7 kg [IQR 2·8 to 4·8] vs 0·6 kg [-0·3 to 1·4], p<0·0001
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885103
04HumanRandomized controlled trialEfficacy outcome
In obese adults, weight loss at 16 weeks was significantly greater with liraglutide than with placebo.
In plain wordsIn obese adults, liraglutide led to more weight loss at 16 weeks than placebo.
Peptide
Liraglutide
Outcome
DecreaseWeight loss at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
There was also significantly greater weight loss in the liraglutide group than in the placebo group (at 5 weeks: median 3·7 kg [IQR 2·8 to 4·8] vs 0·6 kg [-0·3 to 1·4], p<0·0001; at 16 weeks: 5·3 kg [5·2 to 6·8] vs 2·5 kg [0·1 to 4·2], p=0·0009).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885104
05HumanRandomized controlled trialEfficacy outcome
In obese adults, maximum tolerated volume at 16 weeks was numerically lower with liraglutide than with placebo.
In plain wordsIn obese adults, the most food people could take in at 16 weeks was numerically lower with liraglutide than with placebo.
Peptide
Liraglutide
Outcome
No significant changeSatiation (maximum tolerated volume) at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Measurements
Maximum tolerated volume median
750 mL
liraglutide
Maximum tolerated volume median
1126 mL
placebo
Source sentences
Summary
Satiation, as assessed by maximum tolerated volume at 16 weeks, was lower in the liraglutide group (median 750 mL [IQR 651 to 908]) compared with the placebo group (1126 mL [944-1185]; p=0·054).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885105
06HumanRandomized controlled trialEfficacy outcome
In obese adults, volume to fullness at 16 weeks did not differ significantly between liraglutide and placebo.
In plain wordsIn obese adults, the amount of food needed to feel full was not clearly different between liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeVolume to fullness at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were noted between groups in terms of volume to fullness, satiety, or fasting and postprandial gastric volumes at week 16.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885106
07HumanRandomized controlled trialEfficacy outcome
In obese adults, satiety at 16 weeks did not differ significantly between liraglutide and placebo.
In plain wordsIn obese adults, feeling of satiety was not clearly different between liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeSatiety at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were noted between groups in terms of volume to fullness, satiety, or fasting and postprandial gastric volumes at week 16.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885107
08HumanRandomized controlled trialMechanism
In obese adults, fasting gastric volume at 16 weeks did not differ significantly between liraglutide and placebo.
In plain wordsIn obese adults, stomach volume when fasting was not clearly different between liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changeFasting gastric volume at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were noted between groups in terms of volume to fullness, satiety, or fasting and postprandial gastric volumes at week 16.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885108
09HumanRandomized controlled trialMechanism
In obese adults, postprandial gastric volume at 16 weeks did not differ significantly between liraglutide and placebo.
In plain wordsIn obese adults, stomach volume after a meal was not clearly different between liraglutide and placebo.
Peptide
Liraglutide
Outcome
No significant changePostprandial gastric volume at 16 weeks
Study
n = 40
Comparator
Placebo
Analysis
Secondary
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
No significant differences were noted between groups in terms of volume to fullness, satiety, or fasting and postprandial gastric volumes at week 16.
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885109
10HumanRandomized controlled trialMechanism
In obese adults on liraglutide, delay in gastric emptying of solids at 5 weeks correlated with weight loss at 16 weeks in a post-hoc analysis.
In plain wordsIn obese adults on liraglutide, slower stomach emptying at 5 weeks was linked to more weight loss at 16 weeks, in a post-hoc check.
Peptide
Liraglutide
Outcome
Not applicableCorrelation of gastric emptying at 5 weeks with weight change at 16 weeks
Study
n = 40
Analysis
Exploratory
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Post-hoc analysis showed that the T_1/2 of gastric emptying of solids at 5 weeks correlated with change in weight loss at week 16 with liraglutide (Rs 0·567, p=0·018).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885110
11HumanRandomized controlled trialSafety outcome
In obese adults, nausea was the most common adverse event with liraglutide (12 of 19) and was more frequent than with placebo (four of 21).
In plain wordsIn obese adults, nausea was the most common side effect of liraglutide and happened more often than with placebo.
Peptide
Liraglutide
Outcome
IncreaseNausea
Study
n = 40
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
3·0 mg · subcutaneous · 16 weeksAs given in this study (human).
Source sentences
Summary
Nausea was the most common adverse event in the liraglutide group (12 of 19) compared with placebo (four of 21).
2 context sentences(design, population, supporting numbers)
Summary · context
Participants were randomly allocated (1:1) by a computer generated randomisation schedule with no stratification to receive subcutaneous liraglutide (3·0 mg) or placebo, with standardised nutritional and behavioural counselling.
Summary · context
Otherwise healthy, local residents aged 18-65 years with body-mass index (BMI) 30 kg/m² or higher were included.
Report a problemFND-2895885111

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 2 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase not statedNCT06154486

Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study

Hospital Israelita Albert Einsteinn = 3019 Jun 2023 to 22 Aug 2023

Pneumonia, Aspiration · Anesthesia

Trial page ClinicalTrials.govUpdated 4 Dec 2023

CompletedPhase 2Results postedNCT02647944

Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in Obesity

Mayo Clinicn = 4018 Dec 2015 to 30 Dec 2016

Obesity

Trial page ClinicalTrials.govUpdated 27 Oct 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.